Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis.
To explore the relationships between vitamin A, D and E and inflammation in relapsing remitting multiple sclerosis, we assessed their associations with 11 inflammation markers in 9 serial serum samples from 85 patients, before and during interferon-β1a treatment. A negative association was found between vitamin A and pentraxin 3 independent of interferon-β1a use, whereas positive associations between vitamin D and interleukin-1 receptor antagonist and secreted frizzled-related protein 3 were seen before, and between vitamin E and chemokine (C-X-C motif) ligand 16 during interferon-β1a treatment. These findings suggest associations with diverse inflammatory pathways, which may be differentially influenced by interferon-β1a treatment.
Department of Neurology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: egil.rorvik.rosjo@ahus.no.
Egil
E
Røsjø
Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; KG Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Kjell-Morten
KM
Myhr
Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway.
Kristin Ingeleiv
KI
Løken-Amsrud
Department of Neuroradiology, Oslo University Hospital, Oslo, Norway.
Søren Jacob
SJ
Bakke
Multiple Sclerosis Centre Hakadal, Hakadal, Norway.
Antonie G
AG
Beiske
Department of Medical Biochemistry, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Department of Laboratory Medicine, Children´s and Women´s Health, Norwegian University of Science and Technology, Trondheim, Norway.
Kristian S
KS
Bjerve
Department of Neurology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Harald
H
Hovdal
Curato Oslo, Oslo, Norway.
Finn
F
Lilleås
Department of Neurology, Molde Hospital, Molde, Norway; Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, Norway.
Rune
R
Midgard
Unilabs Drammen, Drammen, Norway.
Tom
T
Pedersen
Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Helse Sør-Øst Health Services Research Centre, Akershus University Hospital, Lørenskog, Norway.
Jūratė Saltytė
JS
Benth
Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Øivind
Ø
Torkildsen
Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Stig
S
Wergeland
Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Annika E
AE
Michelsen
Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Section for Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway; KG Jebsen Inflammatory Research Center, University of Oslo, Oslo, Norway.
Pål
P
Aukrust
Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Thor
T
Ueland
Department of Neurology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Trygve
T
Holmøy
D000328:Adult; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D016207:Cytokines / Q000097:blood*; D004281:Docosahexaenoic Acids / Q000627:therapeutic use; D004311:Double-Blind Method; D015118:Eicosapentaenoic Acid / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000188:drug therapy / Q000276:immunology*; D000683:Serum Amyloid P-Component / Q000378:metabolism; D013997:Time Factors; D014801:Vitamin A / Q000097:blood; D014807:Vitamin D / Q000097:blood; D014810:Vitamin E / Q000097:blood; D014815:Vitamins / Q000097:blood*; D000099153:Pentraxins
D015415:Biomarkers; D002097:C-Reactive Protein; D016207:Cytokines; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; D007155:Immunologic Factors; D016899:Interferon-beta; D000683:Serum Amyloid P-Component; D014801:Vitamin A; D014807:Vitamin D; D014810:Vitamin E; D014815:Vitamins; D000099153:Pentraxins
Inflammation; Multiple sclerosis; Vitamin A; Vitamin D; Vitamin E